A Phase 3 interventional study of Ranibizumab and Sham injection in Diabetes Mellitus and Macular Edema, sponsored by Genentech, Inc.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-17.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing ranibizumab in Diabetes Mellitus — 1 open to participants now, 1 under way, none of them phase 3. Ranibizumab · Diabetes Mellitus.
Among the 16 studies testing ranibizumab in Diabetes Mellitus, this one is the 2nd largest by enrollment, is one of 2 that started in 2007, is one of 6 in phase 3, and was the 2nd registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,073 are open to participants now.
Browse Diabetes Mellitus studies →1 of the 16 studies testing ranibizumab in Diabetes Mellitus is open now, in 1 country. Recruiting first, the newest first:
Southeast Retina Center, Georgia · Sites in United States
Ages 18+
By country, each count listing its studies:
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 650 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 89 take children under 18; 182 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 7 · Phase 4 4
First in 2006; this study’s year is marked. 2 started in 2007.
This study's enrollment of 382 is above the median of 80 across 6,026 interventional studies indexed under Diabetes Mellitus.
Median enrollment 46 across the 16 interventional studies. Of the 14 that completed or were terminated, 7 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 16 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
12 studies in Diabetes Mellitus by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 12 finished, 3 (25%) have results posted.
Among the 12 studies in Diabetes Mellitus by Hoffmann-La Roche, this one is the 2nd largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2007, is one of 2 in phase 3, and was the 5th registered.
Hoffmann-La Roche’s Diabetes Mellitus studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing ranibizumab in Diabetes Mellitus, from their registry updates:
Among Hoffmann-La Roche’s 12 in Diabetes Mellitus:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection in patients with clinically significant macular edema with center involvement (CSME-CI) secondary to diabetes mellitus (Type 1 or 2). This study is identical in design to study NCT00473330 (Protocol ID FVF4170g).
The open-label extension phase of the study was stopped after receiving FDA approval of the study drug (ranibizumab) for diabetic macular edema.
This study is composed of 3 phases: (1) A 24-month controlled treatment period (monthly treatment with ranibizumab 0.3 mg, ranibizumab 0.5 mg, or sham injection) followed by (2) a 12-month treatment period in which patients randomized to the sham group who had not discontinued from treatment (still masked) could choose to receive monthly ranibizumab 0.5 mg while the 2 ranibizumab treatment groups continued on the same treatment they received in the first 2 years. Patients who had not discontinued treatment by Month 36 were eligible to continue treatment with ranibizumab 0.5 mg as needed (pro re nata, PRN) in (3) an extension phase of the study for up to 2 more years, resulting in up to 5 years possible total treatment time for some patients.
As per the protocol, Genentech terminated the study approximately 30 days after approval of ranibizumab for diabetic macular edema in the United States.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Concurrent Ocular Conditions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients received ranibizumab 0.3 mg monthly administered intravitreally for 36 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata \[PRN\]) for up to 24 additional months.
Drug: Ranibizumab
Patients received ranibizumab 0.5 mg monthly administered intravitreally for 36 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata \[PRN\]) for up to 24 additional months.
Drug: Ranibizumab
Patients received a sham intravitreal injection monthly for 24 months. Patients who had not discontinued treatment by Month 24 could choose to receive ranibizumab 0.5 mg monthly administered intravitreally for the subsequent 12 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata \[PRN\]) for up to 24 additional months.
Drug: Sham injection
Sterile solution for intravitreal injection.
Also known as: Lucentis
Percentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Month 24
BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.
Time frame: Baseline to Month 24
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at Months 24, 36, and 48
BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision. A positive change score indicates improvement.
Time frame: Baseline to Month 48
Percentage of Patients With a Visual Acuity (VA) Snellen Equivalent of 20/40 or Better at Months 24, 36, and 48
VA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart starting at a test distance of 4 meters. An increase in the number of lines read correctly by the patient in the ETDRS chart indicates an improvement of vision. The Snellen equivalent of 20/40 or better is 69 or more letters correctly read in the EDTRS chart.
Time frame: Months 24, 36, and 48
Percentage of Patients Who Lost < 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Months 24, 36, and 48
BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.
Time frame: Baseline to Month 48
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at Months 24 and 36 in Patients With Focal Edema at Baseline
BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision. A positive change score indicates improvement.
Time frame: Baseline to Month 36
Mean Change From Baseline in Central Foveal Thickness at Months 24, 36, and 48
Central foveal thickness was assessed in optical coherence tomographic images by the central reading center. A decrease in foveal thickness suggests a reduction in macular edema. A negative change score indicates improvement.
Time frame: Baseline to Month 48
Percentage of Patients With a ≥ 3-step Worsening From Baseline in the Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale Score for Eyes at Months 24 and 36
The severity of diabetic retinopathy was graded on a 10-point scale by the central reading center by comparing patient fundus photographic images with a set of standard images. 1=diabetic retinopathy (DR) severity level 10, 12 (DR absent), 2=DR severity level 14A-14C, 14Z, 15, 20 (DR questionable, microaneurysms only), 3=DR severity level 35A-35F (mild non-proliferative \[NP\]DR), 4=DR severity level 43A, 43B (moderate NPDR), 5=DR severity level 47A-47D (moderately severe NPDR), 6=DR severity level 53A-53E (severe NPDR), 7=DR severity level 60, 61A, 61B (mild proliferative \[P\]DR), 8=DR severity level 65A-65C (moderate PDR), 9=DR severity level 71A-71D (high-risk PDR), 10=DR severity level 90 (cannot grade). A lower score indicates less severe diabetic retinopathy.
Time frame: Baseline to Month 36
Percentage of Patients With Resolution of Leakage at Month 24
Resolution of leakage was defined as total area of fluorescein leakage in the central, inner, and outer subfields of the 0 Disc Area. Leakage was assessed in fluorescein angiographic images by the central reading center.
Time frame: Baseline to Month 24
Mean Number of Macular Laser Treatments From Baseline Through Months 24 and 36
The need for macular laser treatment was evaluated by the masked (evaluating) physician. Macular laser was administered per protocol-specified objective and subjective criteria starting at Month 3.
Time frame: Baseline to Month 36
Percentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Months 36 and 48
BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.
Time frame: Baseline to Month 48
Mean Change From Month 36 in Best Corrected Visual Acuity (BCVA) Score in the Study Eye at Month 48
BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision. A positive change score indicates improvement.
Time frame: Month 36 to Month 48
Percentage of Patients Who Lost < 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score in the Study Eye From Month 36 at Month 48
BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.
Time frame: Month 36 to Month 48
Mean Change From Month 36 in Central Foveal Thickness in the Study Eye at Month 48
Central foveal thickness was assessed in optical coherence tomographic images by the central reading center. A decrease in foveal thickness suggests a reduction in macular edema. A negative change score indicates improvement.
Time frame: Month 36 to Month 48
Patients were recruited from study sites in the United States, Argentina, Peru, Columbia, Chile, and Peru. There were 47 patients from the Latin American countries.
| Milestone | Sham Injection/Ranibizumab 0.5 mg | Ranibizumab 0.3 mg | Ranibizumab 0.5 mg |
|---|---|---|---|
| Started | 130 | 125 | 127 |
| Completed | 102 | 98 | 98 |
| Not completed | 28 | 27 | 29 |
| Withdrew: Adverse event | 3 | 1 | 1 |
| Withdrew: Death | 3 | 5 | 10 |
| Withdrew: Lost to follow-up | 3 | 3 | 3 |
| Withdrew: Physician decision | 1 | 2 | 2 |
| Withdrew: Subject non-compliance | 5 | 2 | 1 |
| Withdrew: Subject needed other treatment | 1 | 3 | 2 |
| Withdrew: Subject's decision | 12 | 11 | 10 |
| Milestone | Sham Injection/Ranibizumab 0.5 mg | Ranibizumab 0.3 mg | Ranibizumab 0.5 mg |
|---|---|---|---|
| Started | 88 | 83 | 84 |
| Completed | 38 | 42 | 37 |
| Not completed | 50 | 41 | 47 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Withdrew: Death | 1 | 3 | 3 |
| Withdrew: Lost to follow-up | 1 | 2 | 1 |
| Withdrew: Subject's decision | 5 | 1 | 6 |
| Withdrew: Sponsor's decision to terminate study | 41 | 34 | 36 |
| Withdrew: Subject required other intervention | 2 | 1 | 0 |
| Milestone | Sham Injection/Ranibizumab 0.5 mg | Ranibizumab 0.3 mg | Ranibizumab 0.5 mg |
|---|---|---|---|
| Started | 88 | 83 | 84 |
| Completed | 2 | 1 | 2 |
| Not completed | 86 | 82 | 82 |
| Withdrew: Adverse event | 0 | 0 | 2 |
| Withdrew: Death | 1 | 7 | 4 |
| Withdrew: Lost to follow-up | 1 | 3 | 1 |
| Withdrew: Subject's decision | 7 | 1 | 6 |
| Withdrew: Sponsor's decision to terminate study | 75 | 70 | 69 |
| Withdrew: Subject required other intervention | 2 | 1 | 0 |
BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.
| Percentage of patients | Ranibizumab 0.3 mg | Ranibizumab 0.5 mg | Sham Injection |
|---|---|---|---|
| Percentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Month 24 | 33.6 (25.3 to 41.9) | 45.7 (37.0 to 54.3) | 12.3 (6.7 to 18.0) |
BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision. A positive change score indicates improvement.
| Letters | Ranibizumab 0.3 mg | Ranibizumab 0.5 mg | Sham Injection | Sham Injection/Ranibizumab 0.5 mg |
|---|---|---|---|---|
| Month 24 | 10.9 ± 10.4 | 12.0 ± 14.9 | 2.3 ± 14.2 | NA ± NA |
| Month 36 | 10.6 ± 12.9 | 11.4 ± 16.3 | NA ± NA | 4.7 ± 13.3 |
| Month 48 (n=34,39,39,0) | 11.1 ± 12.0 | 12.4 ± 9.7 | NA ± NA | 4.6 ± 12.8 |
VA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart starting at a test distance of 4 meters. An increase in the number of lines read correctly by the patient in the ETDRS chart indicates an improvement of vision. The Snellen equivalent of 20/40 or better is 69 or more letters correctly read in the EDTRS chart.
| Percentage of patients | Ranibizumab 0.3 mg | Ranibizumab 0.5 mg | Sham Injection | Sham Injection/Ranibizumab 0.5 mg |
|---|---|---|---|---|
| Month 24 | 54.4 (45.7 to 63.1) | 62.2 (53.8 to 70.6) | 34.6 (26.4 to 42.8) | NA (NA to NA) |
| Month 36 | 55.2 (46.5 to 63.9) | 59.1 (50.5 to 67.6) | NA (NA to NA) | 42.3 (33.8 to 50.8) |
| Month 48 (n=39,39,0,34) | 64.1 (47.2 to 78.8) | 56.4 (39.6 to 72.2) | NA (NA to NA) | 47.1 (29.8 to 64.9) |
BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.
| Percentage of patients | Ranibizumab 0.3 mg | Ranibizumab 0.5 mg | Sham Injection | Sham Injection/Ranibizumab 0.5 mg |
|---|---|---|---|---|
| Month 24 | 98.4 (96.2 to 100.0) | 96.1 (92.7 to 99.4) | 91.5 (86.8 to 96.3) | NA (NA to NA) |
| Month 36 | 96.8 (93.7 to 99.9) | 96.1 (92.7 to 99.4) | NA (NA to NA) | 92.3 (87.7 to 96.9) |
| Month 48 (n=39,39,0,34) | 97.4 (86.5 to 99.9) | 97.4 (86.5 to 99.9) | NA (NA to NA) | 94.1 (80.3 to 99.3) |
BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision. A positive change score indicates improvement.
| Letters | Ranibizumab 0.3 mg | Ranibizumab 0.5 mg | Sham Injection | Sham Injection/Ranibizumab 0.5 mg |
|---|---|---|---|---|
| Month 24 | 10.5 ± 11.9 | 12.8 ± 11.0 | 1.9 ± 17.0 | NA ± NA |
| Month 36 | 10.8 ± 12.1 | 10.9 ± 16.6 | NA ± NA | 6.6 ± 14.4 |
Central foveal thickness was assessed in optical coherence tomographic images by the central reading center. A decrease in foveal thickness suggests a reduction in macular edema. A negative change score indicates improvement.
| µm | Ranibizumab 0.3 mg | Ranibizumab 0.5 mg | Sham Injection | Sham Injection/Ranibizumab 0.5 mg |
|---|---|---|---|---|
| Month 24 | -259.8 ± 169.3 | -270.7 ± 201.6 | -125.8 ± 198.3 | NA ± NA |
| Month 36 | -261.8 ± 180.8 | -266.7 ± 207.8 | NA ± NA | -213.2 ± 193.5 |
| Month 48 (n=38,39,0,33) | -251.4 ± 173.8 | -291.6 ± 200.7 | NA ± NA | -258.7 ± 182.3 |
The severity of diabetic retinopathy was graded on a 10-point scale by the central reading center by comparing patient fundus photographic images with a set of standard images. 1=diabetic retinopathy (DR) severity level 10, 12 (DR absent), 2=DR severity level 14A-14C, 14Z, 15, 20 (DR questionable, microaneurysms only), 3=DR severity level 35A-35F (mild non-proliferative \[NP\]DR), 4=DR severity level 43A, 43B (moderate NPDR), 5=DR severity level 47A-47D (moderately severe NPDR), 6=DR severity level 53A-53E (severe NPDR), 7=DR severity level 60, 61A, 61B (mild proliferative \[P\]DR), 8=DR severity level 65A-65C (moderate PDR), 9=DR severity level 71A-71D (high-risk PDR), 10=DR severity level 90 (cannot grade). A lower score indicates less severe diabetic retinopathy.
| Percentage of patients | Ranibizumab 0.3 mg | Ranibizumab 0.5 mg | Sham Injection | Sham Injection/Ranibizumab 0.5 mg |
|---|---|---|---|---|
| Month 24 | 1.7 (0 to 4.1) | 0 (0 to 0) | 5.6 (1.6 to 9.7) | NA (NA to NA) |
| Month 36 | 0.9 (0 to 2.5) | 0.8 (0 to 2.5) | NA (NA to NA) | 3.2 (0.1 to 6.3) |
Resolution of leakage was defined as total area of fluorescein leakage in the central, inner, and outer subfields of the 0 Disc Area. Leakage was assessed in fluorescein angiographic images by the central reading center.
| Percentage of patients | Ranibizumab 0.3 mg | Ranibizumab 0.5 mg | Sham Injection |
|---|---|---|---|
| Percentage of Patients With Resolution of Leakage at Month 24 | 17.1 (10.4 to 23.7) | 30.7 (22.7 to 38.7) | 2.3 (0 to 4.9) |
The need for macular laser treatment was evaluated by the masked (evaluating) physician. Macular laser was administered per protocol-specified objective and subjective criteria starting at Month 3.
| Treatments | Ranibizumab 0.3 mg | Ranibizumab 0.5 mg | Sham Injection | Sham Injection/Ranibizumab 0.5 mg |
|---|---|---|---|---|
| Month 24 | 0.7 ± 1.4 | 0.3 ± 0.7 | 1.6 ± 1.6 | NA ± NA |
| Month 36 | 0.9 ± 1.8 | 0.4 ± 0.9 | NA ± NA | 1.7 ± 1.6 |
BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.
| Percentage of patients | Ranibizumab 0.3 mg | Ranibizumab 0.5 mg | Sham Injection/Ranibizumab 0.5 mg |
|---|---|---|---|
| Month 36 | 36.8 (28.3 to 45.3) | 40.2 (31.6 to 48.7) | 19.2 (12.5 to 26.0) |
| Month 48 (n=39,39,34) | 48.7 (32.4 to 65.2) | 41.0 (25.6 to 57.9) | 17.6 (6.8 to 34.5) |
BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision. A positive change score indicates improvement.
| Letters | Ranibizumab 0.3 mg | Ranibizumab 0.5 mg | Sham Injection/Ranibizumab 0.5 mg |
|---|---|---|---|
| Mean Change From Month 36 in Best Corrected Visual Acuity (BCVA) Score in the Study Eye at Month 48 | -0.9 ± 8.3 | 0.3 ± 10.7 | -2.6 ± 8.8 |
BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.
| Percentage of patients | Ranibizumab 0.3 mg | Ranibizumab 0.5 mg | Sham Injection/Ranibizumab 0.5 mg |
|---|---|---|---|
| Percentage of Patients Who Lost < 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score in the Study Eye From Month 36 at Month 48 | 92.3 (79.1 to 98.4) | 97.4 (86.5 to 99.9) | 88.2 (72.5 to 96.7) |
Central foveal thickness was assessed in optical coherence tomographic images by the central reading center. A decrease in foveal thickness suggests a reduction in macular edema. A negative change score indicates improvement.
| µm | Ranibizumab 0.3 mg | Ranibizumab 0.5 mg | Sham Injection/Ranibizumab 0.5 mg |
|---|---|---|---|
| Mean Change From Month 36 in Central Foveal Thickness in the Study Eye at Month 48 | 46.1 ± 148.1 | 44.1 ± 86.3 | 9.6 ± 78.9 |
Collected over Adverse events were recorded from the first day of treatment through Month 60. The sham Months 0-36 group includes patients randomized to sham. The sham Months 0-24 group includes patients who received sham during the first 24 months of the study.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sham Injection - Months 0-24 | — | 54/127 (42.5%) | 123/127 (96.9%) |
| Sham Injection/Ranibizumab 0.5 mg - Months 0-36 | — | 68/127 (53.5%) | 123/127 (96.9%) |
| Ranibizumab 0.3 mg - Months 0-36 | — | 54/125 (43.2%) | 120/125 (96%) |
| Ranibizumab 0.5 mg - Months 0-36 | — | 67/124 (54%) | 121/124 (97.6%) |
| Sham Injection/Ranibizumab 0.5 mg - Months 37-60 | — | 19/88 (21.6%) | 65/88 (73.9%) |
| Ranibizumab 0.3 mg - Months 37-60 | — | 31/83 (37.3%) | 63/83 (75.9%) |
| Ranibizumab 0.5 mg - Months 37-60 | — | 18/84 (21.4%) | 62/84 (73.8%) |
| Event | Sham Injection - Months 0-24 | Sham Injection/Ranibizumab 0.5 mg - Months 0-36 | Ranibizumab 0.3 mg - Months 0-36 | Ranibizumab 0.5 mg - Months 0-36 | Sham Injection/Ranibizumab 0.5 mg - Months 37-60 | Ranibizumab 0.3 mg - Months 37-60 | Ranibizumab 0.5 mg - Months 37-60 |
|---|---|---|---|---|---|---|---|
| Vitreous haemorrhage (F)Eye disorders | 2/127 | 3/127 | 10/125 | 4/124 | 0/88 | 0/83 | 0/84 |
| PneumoniaInfections and infestations | 5/127 | 5/127 | 1/125 | 8/124 | 2/88 | 1/83 | 1/84 |
| Myocardial infarctionCardiac disorders | 6/127 | 7/127 | 8/125 | 3/124 | 0/88 | 3/83 | 0/84 |
| Cardiac failure congestiveCardiac disorders | 6/127 | 7/127 | 3/125 | 4/124 | 5/88 | 2/83 | 2/84 |
| Coronary artery diseaseCardiac disorders | 1/127 | 3/127 | 2/125 | 6/124 | 0/88 | 2/83 | 0/84 |
| Renal failure acuteRenal and urinary disorders | 2/127 | 2/127 | 2/125 | 1/124 | 1/88 | 3/83 | 1/84 |
| Cerebrovascular accidentNervous system disorders | 2/127 | 2/127 | 3/125 | 4/124 | 0/88 | 2/83 | 2/84 |
| Renal failureRenal and urinary disorders | 3/127 | 4/127 | 3/125 | 4/124 | 1/88 | 1/83 | 1/84 |
| Acute myocardial infarctionCardiac disorders | 0/127 | 2/127 | 4/125 | 1/124 | 0/88 | 1/83 | 1/84 |
| Vitreous haemorrhage (S)Eye disorders | 3/127 | 4/127 | 1/125 | 0/124 | 0/88 | 1/83 | 1/84 |
| Event | Sham Injection - Months 0-24 | Sham Injection/Ranibizumab 0.5 mg - Months 0-36 | Ranibizumab 0.3 mg - Months 0-36 | Ranibizumab 0.5 mg - Months 0-36 | Sham Injection/Ranibizumab 0.5 mg - Months 37-60 | Ranibizumab 0.3 mg - Months 37-60 | Ranibizumab 0.5 mg - Months 37-60 |
|---|---|---|---|---|---|---|---|
| Conjunctival haemorrhage (S)Eye disorders | 40/127 | 45/127 | 54/125 | 63/124 | 7/88 | 4/83 | 6/84 |
| Macular oedema (F)Eye disorders | 28/127 | 37/127 | 46/125 | 53/124 | 10/88 | 8/83 | 9/84 |
| Cataract (F)Eye disorders | 29/127 | 32/127 | 38/125 | 41/124 | 5/88 | 1/83 | 3/84 |
| Retinal haemorrhage (F)Eye disorders | 20/127 | 31/127 | 32/125 | 40/124 | 6/88 | 9/83 | 8/84 |
| Cataract (S)Eye disorders | 35/127 | 39/127 | 31/125 | 35/124 | 5/88 | 6/83 | 5/84 |
| HypertensionVascular disorders | 31/127 | 35/127 | 33/125 | 38/124 | 5/88 | 3/83 | 3/84 |
| Retinal haemorrhage (S)Eye disorders | 22/127 | 26/127 | 22/125 | 34/124 | 4/88 | 9/83 | 7/84 |
| Macular oedema (S)Eye disorders | 26/127 | 33/127 | 32/125 | 26/124 | 9/88 | 6/83 | 9/84 |
| Intraocular pressure increased (S)Investigations | 14/127 | 17/127 | 20/125 | 25/124 | 2/88 | 2/83 | 3/84 |
| Diabetic retinal oedema (F)Eye disorders | 19/127 | 20/127 | 25/125 | 16/124 | 2/88 | 0/83 | 1/84 |
The Baseline Characteristics of the patients enrolled in the open-label extension phase (N=88, 83, 84 patients originally randomized to the ranibizumab 0.3 mg, ranibizumab 0.5 mg, and sham injection groups, respectively) were similar to the Baseline Characteristics of the patients enrolled in the core study.
| Age, Continuous(years) | Ranibizumab 0.3 mg | Ranibizumab 0.5 mg | Sham Injection | Total |
|---|---|---|---|---|
| Mean | 62.7 ± 11.1 | 61.8 ± 10.1 | 63.5 ± 10.8 | 62.7 ± 10.7 |
| Sex: Female, Male(Participants) | Ranibizumab 0.3 mg | Ranibizumab 0.5 mg | Sham Injection | Total |
|---|---|---|---|---|
| Female | 52 | 47 | 64 | 163 |
| Male | 73 | 80 | 66 | 219 |
No study locations are listed for this record.
The record gives a start of Jun 2007, a primary completion of Jan 2011 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2013, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab